PRME Prime Medicine Inc

$PRME I do think the 2.7-4.7 consolidation is ending or has ended . Deal or offering soon but the FDA news was a very big deal

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits $PRME $BEAM $NTLA $EDIT $CRSP https://stocktwits.com/news/equity/markets/prme-beam-edit-ntla-crsp-stocks-gain-as-fda-signals-faster-route-for-patient-specific-gene-edits/cZU9Y9vR9GV

$PRME Cut these trading shares loose again. Core remains untouched, but couldn’t let such a huge gain in less than a week disappear.

$PRME Added most back today, less than 500k shares dropped this 10%. Right above the 50DMA, let’s see if that holds or we heading back to the bottom of the range.

$PRME Can see one more big shakeout from here before higher. Trimmed some trading shares here at $4, if we dip back below $3.50 will readd. Have not touched my core.

$PRME If they dilute, i think it'll be the last chance to grab shares cheap. Cash the only issue currently IMO.

$PRME this js bullish for any biotech that has the technology to edit DNA. Ai helps with sequence discovery and opens the field to discover more sites. Companies like $NTLA $PRME $CRSP have a moat in delivering the editing tools. Ai finds more diseases to treat.

Here are the Final 3 Stocks in My Day Trading Watch List Video for October 28th in About 3 Minutes: $PRME $NFLX $BA .

$PRME But I have nothing new to say about this name ... and that's not bad considering the bloody weeks lately in hundreds of stocks ... The price keeps inside that box, just consuming time. Weekly chart.

$PRME when the first patient serologic markers improve, they will have a PR that will change the trajectory of the SP.

$PRME Not to restate the obvious, but the biggest worry for PRME is not the tech or pipelines, it’s the bond markets and the resulting forecast adjustments, high interest rates to raise funds, and uncertainty in keeping their pipelines funded. They should be better capitalized than where they are. So the better figure something if/before the bond market turns worse - its real - Caribou fell ‘cos of that, but it was made worse by their more uncertain pipelines.

$PRME After that long term resistance breakout ... it looks like the price is testing that former resistance (4-4.4 range at this point ) and trying to turn into support. Keep that way, ok? ( nobody wants a fake breakout ). GL. Weekly chart

$PRME Prime Medicine has a 2026 AASLD “Poster of Distinction” for PM577a AASLD’s regular abstract supplement includes Prime Medicine abstract 1061, “Liver-Directed Prime Editing Corrects ATP7B p.H1069Q and Restores Copper Handling in Wilson Disease Models.” It is designated a Poster of Distinction—AASLD’s designation for top-ranked posters—and is scheduled for November 5.

$PRME more positive news likely tomorrow. The FDA has scheduled a public meeting for October 28, 2026, focused on tailoring regulatory review to the realities of rare diseases. The initiative emphasizes greater flexibility, clearer regulatory expectations, and evidence appropriate to small patient population.

$PRME Ironically, if the low dose works, the 1st Wilson's dease patient is probably cured by now.

$PRME 3rd test of this trendline and a bull flag. if this breaks above with volume we rip

$PRME one thing that worries me is anthropic and the frontier labs are starting to dip their toes into biotech. A trillion dollar behemoth company with endless resources will destroy these small caps. Keeping my positions small! I’m still hopeful, just skeptical!

$PRME they need cash, anyone weary that with this bump in stock price we see an offering pop up soon?

$PRME As much as I know that this is probably a good time to take profits because we never have 2 big up days in a row, I just can't do it!

$PRME $BEAM “Dr. David Liu told me that an estimated 400 million people worldwide have a genetic disease. About 25 million of them are in this country.” https://www.bloomberg.com/news/features/2026-10-21/gene-editing-is-still-pushing-to-be-the-healthcare-industry-s-next-big-thing